Kyoto University Innovation Capital Co., Ltd. ("Kyoto-iCAP") (Head Office: Sakyo-ku, Kyoto; Representative Director: Ko Kusumi) is pleased to announce that Chordia Therapeutics Inc. (Head Office: Fujisawa-shi, Kanagawa; Representative Director: Hiroshi Miyake), Kyoto-iCAP has supported since its establishment, was listed on the Tokyo Stock Exchange Growth Market on June 14, 2024. This is the fourth IPO exit for Kyoto-iCAP's portfolio companies.

■ Chordia Therapeutics Inc. Press Release
https://www.chordiatherapeutics.com/ja/news/news2048427766054893309/main/0/link/JP_Notice%20of%20Listing_20240614.pdf

■ Chordia Therapeutics, Inc. IR Information
https://www.chordiatherapeutics.com/ja/ir.html

About Chordia Therapeutics, Inc.
Summary: Biotech to Develop Anticancer Drugs Focusing on RNA Regulatory Stress Abnormalities
Established: November 2017
Location: 2-26-1 Muraoka Higashi, Fujisawa City, Kanagawa Prefecture
Representative: Hiroshi Miyake, CEO
URL:https://www.chordiatherapeutics.com